中文导读
肺是人体最大的外界界面。本文介绍气道与肺泡芯片模型及其在吸入毒理学研究中的应用。
以下为英文全文（English full text）
1. Introduction: The Lung as a Gateway for Environmental and Therapeutic Exposures
The lung represents the body's largest interface with the external environment, with a total surface area of approximately 70–100 m² in adults. This extensive surface facilitates efficient gas exchange but also renders the lung uniquely vulnerable to inhaled pathogens, pollutants, allergens, and therapeutic aerosols. Traditional in vitro models for inhalation toxicology—immortalized cell lines cultured in submerged conditions—fail to recapitulate the critical air-liquid interface (ALI), mechanical forces of breathing, and immune cell interactions that determine pulmonary responses to inhaled agents [1].
Lung-on-chip (LoC) technology addresses these limitations by creating microfluidic models that replicate the alveolar-capillary interface and the airway epithelium with dynamic mechanical forces, enabling physiologically relevant assessment of inhalation toxicity, particle deposition, drug delivery, and infectious disease mechanisms [2].
2. Pulmonary Physiology and Structural Organization
The respiratory system comprises conducting airways (trachea, bronchi, bronchioles) and respiratory units (respiratory bronchioles, alveolar ducts, alveoli). Key physiological parameters relevant to LoC design include:
Airway Anatomy
- Tracheal diameter: ~18–20 mm
- Bronchiolar diameter: 0.5–1.0 mm
- Terminal bronchiolar diameter: ~0.3 mm
- Airway epithelium height: 30–60 μm (pseudostratified columnar)
- Ciliary beat frequency: 8–15 Hz
- Mucociliary clearance velocity: 1–20 mm/min
Alveolar Structure
- Alveolar diameter: 200–300 μm
- Alveolar wall thickness: 0.5–2.0 μm
- Capillary blood flow velocity: 100–500 μm/s
- Surface tension: 25–30 mN/m (with surfactant); 50–70 mN/m (without)
- Respiratory rate: 12–20 breaths/min (resting)
- Tidal volume: 500 mL (adult)
- Intrapleural pressure swing: -5 to -10 cmH₂O (inspiration)
- Alveolar-capillary barrier stretch: 5–15% cyclic strain
3. Alveolar Lung-on-Chip Design and Construction
3.1 The Original Lung-on-Chip Paradigm
Huh et al. (2010) at the Wyss Institute developed the iconic alveolar lung-on-chip, which remains the foundational design for most subsequent platforms [3]. The device consists of two parallel microchannels separated by a thin, flexible, porous PDMS membrane (10 μm thick, 10 μm pores):
- Upper channel (alveolar compartment): Seeded with human alveolar epithelial cells (A549 or primary alveolar type II cells) and exposed to air (air-liquid interface)
- Lower channel (vascular compartment): Seeded with human pulmonary microvascular endothelial cells and perfused with culture medium
- Side vacuum chambers: Apply cyclic suction to stretch the membrane, mimicking physiological breathing motions (5–15% strain at 0.2 Hz)
This design recreates the alveolar-capillary interface with mechanical breathing motions, enabling study of nanoparticle translocation, inflammatory responses, and drug permeability under dynamic conditions [3].
Key Technical Parameters
- Channel dimensions: 1000 μm (width) × 100 μm (height) × 20 mm (length)
- Membrane: PDMS, 10 μm thick, 10 μm pores at 5×10⁶ pores/cm²
- Vacuum pressure: -20 to -40 kPa (applied to side chambers)
- Cyclic strain: 5–15% at 0.2 Hz (12 breaths/min)
- Medium flow rate: 30–60 μL/min (vascular channel)
- Temperature: 37°C with humidified gas supply (5% CO₂, air)
Air-Liquid Interface (ALI) Maintenance
The apical surface of the alveolar epithelium must be exposed to air rather than submerged medium. This is achieved by initially filling both channels with medium, allowing cells to attach to the membrane, then gradually removing apical medium to establish the ALI. Continuous humidification of the air supply prevents epithelial desiccation. Primary alveolar type II cells differentiate into type I-like cells under ALI conditions, expressing surfactant proteins (SP-A, SP-B, SP-C, SP-D) and forming tight junctions [2].
4. Airway Lung-on-Chip and Small Airway Models
4.1 Airway-on-Chip with Ciliated Epithelium
Airway chips model the bronchial epithelium with mucociliary clearance function. Primary human bronchial epithelial cells (HBECs) or iPSC-derived airway cells are cultured at ALI on porous membranes, forming pseudostratified epithelium with basal, goblet, and ciliated cells. Co-culture with airway smooth muscle cells in adjacent channels enables study of bronchoconstriction and asthma mechanisms. Benam et al. (2017) established a human small airway-on-chip protocol demonstrating mucociliary differentiation and response to IL-13 stimulation [4].
4.2 Microengineered Suspended Gels
Humayun et al. (2018) developed an airway-on-chip with arrayable suspended gels that better replicate the curved airway geometry. Collagen or Matrigel gels are suspended across microchannels, with epithelial cells cultured on the gel surface and smooth muscle cells on the channel floor. This design enables contraction/relaxation measurements and imaging of epithelial-mesenchymal interactions [5].
4.3 Small Airway Disease Models
Chronic obstructive pulmonary disease (COPD) and asthma involve small airway remodeling (<2 mm diameter). Microfluidic platforms with reduced channel dimensions (100–300 μm width) and co-culture with fibroblasts and immune cells recreate the inflammatory microenvironment of small airway disease. Cigarette smoke extract (CSE) exposure, allergen challenge (house dust mite, Alternaria), and viral infection (rhinovirus, influenza) can be modeled under physiologically relevant ALI conditions [6].
5. Technical Specifications and Operating Parameters
6. Functional Validation and Toxicity Assessment
Barrier Integrity
- Trans-epithelial electrical resistance (TEER): 200–1000 Ω·cm² for healthy epithelium; <200 Ω·cm² indicates barrier disruption
- FITC-dextran permeability (4–70 kDa)
- Immunostaining for tight junctions (ZO-1, occludin, claudin-1), adherens junctions (E-cadherin), and basement membrane (collagen IV, laminin)
- Scanning electron microscopy (SEM) for microvilli and cilia ultrastructure
Cellular Differentiation Markers
- Alveolar epithelium: Surfactant proteins (SP-A, SP-B, SP-C, SP-D), aquaporin-5, T1α (podoplanin)
- Airway epithelium: Muc5AC (goblet cells), β-tubulin IV (cilia), FOXJ1 (ciliated cells), p63 (basal cells), CC10 (Clara cells)
- Endothelium: VE-cadherin, CD31, vWF, PECAM-1
Mechanical Function
- Ciliary beat frequency (high-speed video microscopy): 8–15 Hz
- Mucociliary transport velocity (fluorescent bead tracking): 1–20 mm/min
- Bronchoconstriction/relaxation: Contraction of smooth muscle cells in response to methacholine or histamine; relaxation in response to salbutamol (β2-agonist)
- Surfactant activity: Surface tension measurements using pulsating bubble surfactometry
Toxicity and Inflammation Endpoints
- Cell viability (LDH, ATP, live/dead staining)
- Cytokine release (IL-6, IL-8, TNF-α, MCP-1, G-CSF, MIP-1α/β)
- Reactive oxygen species (ROS)
- Barrier disruption (TEER, paracellular permeability)
- Inflammatory cell recruitment (neutrophil transmigration across the epithelial-endothelial barrier)
- Macrophage activation and phagocytosis (using THP-1 or primary alveolar macrophages)
7. Inhalation Toxicology and Drug Delivery Applications
Nanoparticle and Environmental Toxicity
The lung-on-chip is uniquely suited for studying airborne particle toxicity. Silica nanoparticles, titanium dioxide (TiO₂), zinc oxide (ZnO), and carbon nanotubes can be introduced through the apical air channel at ALI. Mechanical stretching enhances nanoparticle uptake and inflammatory responses compared to static cultures, demonstrating the importance of physiological mechanical forces in nanotoxicology [3].
Drug-Induced Pulmonary Toxicity
Amiodarone, bleomycin, and methotrexate are known causes of drug-induced pulmonary toxicity. Lung-on-chip platforms can identify mechanistic pathways including epithelial barrier disruption, surfactant dysfunction, fibroblast activation, and immune cell infiltration. The ability to incorporate patient-specific iPSC-derived cells enables investigation of genetic susceptibility factors in pulmonary drug reactions [7].
Inhalation Drug Delivery
Aerosol deposition and absorption of inhaled therapeutics (bronchodilators, corticosteroids, antibiotics, mRNA-LNP formulations) can be studied using lung-on-chip platforms with direct aerosol exposure systems. Devices such as the AlveoliX lung-on-chip and CFAX12 platform integrate aerosol generators with ALI culture, enabling real-time assessment of drug deposition, barrier permeability, and cellular responses under breathing-like stretch conditions [8].
Infectious Disease Modeling
Bacterial (Pseudomonas aeruginosa, Streptococcus pneumoniae), viral (influenza, SARS-CoV-2, respiratory syncytial virus), and fungal (Aspergillus fumigatus) pathogens can be introduced to the apical airway surface. Lung-on-chip models of COVID-19 demonstrated SARS-CoV-2 infection of alveolar epithelial cells, barrier disruption, and inflammatory cytokine release, providing a platform for antiviral drug screening and mechanism studies [2].
8. Conclusion
Lung-on-chip technology provides an unparalleled platform for inhalation toxicology, pulmonary drug delivery, and respiratory disease modeling. By recreating the air-liquid interface, mechanical breathing motions, and tissue-tissue interactions of the human lung, these devices generate predictive data that static cultures and animal models cannot replicate. GBiowit offers advanced lung-on-chip platforms, specialized airway and alveolar cell-compatible media, ECM matrices, and comprehensive inhalation toxicology screening services.